Small molecule · developed by AstraZeneca
Laroprovstat/Rosuvastatin 2 is a fixed-dose combination given as a daily oral dose.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07930507 | Phase 3 | Hypercholesterolemia | Not yet recruiting | AZN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hypercholesterolemia
Updated Nov 15, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →